Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interim FDG-PET improves treatment failure prediction in primary central nervous system Lymphoma: a LOC network prospective multicentric study.
Rozenblum L, Houillier C, Baptiste A, Soussain C, Edeline V, Naggara P, Soret M, Causse-Lemercier V, Willems L, Choquet S, Ursu R, Galanaud D, Belin L, Hoang-Xuan K, Kas A. Rozenblum L, et al. Among authors: causse lemercier v. Neuro Oncol. 2024 Feb 16:noae029. doi: 10.1093/neuonc/noae029. Online ahead of print. Neuro Oncol. 2024. PMID: 38366824
[18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network.
Rozenblum L, Galanaud D, Houillier C, Soussain C, Baptiste A, Belin L, Edeline V, Naggara P, Soret M, Causse-Lemercier V, Willems L, Choquet S, Ursu R, Hoang-Xuan K, Kas A. Rozenblum L, et al. Among authors: causse lemercier v. Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3684-3696. doi: 10.1007/s00259-023-06334-w. Epub 2023 Jul 18. Eur J Nucl Med Mol Imaging. 2023. PMID: 37462774
Brain Metabolic Profile in Presymptomatic GRN Carriers Throughout a 5-Year Follow-up.
Saracino D, Sellami L, Boniface H, Houot M, Pélégrini-Issac M, Funkiewiez A, Rinaldi D, Locatelli M, Azuar C, Causse-Lemercier V, Jaillard A, Pasquier F, Chastan M, Wallon D, Hitzel A, Pariente J, Pallardy A, Boutoleau-Bretonnière C, Guedj E, Didic M, Migliaccio R, Kas A, Habert MO, Le Ber I; Predict-PGRN. Saracino D, et al. Among authors: causse lemercier v. Neurology. 2023 Jan 24;100(4):e396-e407. doi: 10.1212/WNL.0000000000201439. Epub 2022 Oct 18. Neurology. 2023. PMID: 36257714
Ultra-low-dose in brain 18F-FDG PET/MRI in clinical settings.
Soret M, Maisonobe JA, Desarnaud S, Bergeret S, Causse-Lemercier V, Berenbaum A, Rozenblum L, Habert MO, Kas A. Soret M, et al. Among authors: causse lemercier v. Sci Rep. 2022 Sep 12;12(1):15341. doi: 10.1038/s41598-022-18029-7. Sci Rep. 2022. PMID: 36097015 Free PMC article.
Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications.
Saracino D, Dorgham K, Camuzat A, Rinaldi D, Rametti-Lacroux A, Houot M, Clot F, Martin-Hardy P, Jornea L, Azuar C, Migliaccio R, Pasquier F, Couratier P, Auriacombe S, Sauvée M, Boutoleau-Bretonnière C, Pariente J, Didic M, Hannequin D, Wallon D; French Research Network on FTD/FTD-ALS; PREV-DEMALS and Predict-PGRN study groups; Colliot O, Dubois B, Brice A, Levy R, Forlani S, Le Ber I. Saracino D, et al. J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1278-1288. doi: 10.1136/jnnp-2021-326914. Epub 2021 Aug 4. J Neurol Neurosurg Psychiatry. 2021. PMID: 34349004 Free PMC article.
Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds.
Habert MO, Bertin H, Labit M, Diallo M, Marie S, Martineau K, Kas A, Causse-Lemercier V, Bakardjian H, Epelbaum S, Chételat G, Houot M, Hampel H, Dubois B, Mangin JF; INSIGHT-AD study group. Habert MO, et al. Among authors: causse lemercier v. Ann Nucl Med. 2018 Feb;32(2):75-86. doi: 10.1007/s12149-017-1221-0. Epub 2017 Dec 7. Ann Nucl Med. 2018. PMID: 29218458